Sex- and frequency-dependent acute pharmacokinetic and pharmacodynamic effects of smoked cannabis: a randomized controlled trial
Cannabis use is rising among women. Studies suggest females are more sensitive to the intoxicating and misuse-related effects of delta-9-tetrahydrocannabinol (THC). While preclinical studies point to sex-specific development of tolerance, this has not been translated to humans. In this randomized, double-blind, placebo-controlled crossover study, 44 participants (22 F) smoked three cannabis strengths (0% [~0 mg] THC, 4% [~20 mg] THC, 10% [~60 mg] THC), provided blood for plasma analysis, and completed subjective mood and drug effects assessments and a self-administration task. Outcomes were analyzed by cannabis strength, sex, and use frequency ( > 4 vs. ≤4 days/week; balanced across sex). Relative to placebo, active cannabis strengths increased subjective effects and plasma THC and metabolites (ps < 0.05). Exploratory follow-up of interactions (cannabis strength*frequency p < 0.10) showed the frequent-use group exhibiting significant increases from placebo in misuse-related ratings ("Like", "Take again") and self-administering more cannabis than the occasional-use group (ps < 0.05), and this was not modified by sex. Ratings of "High", Sedation/impairment, Dysphoric arousal, and "Bad effect" were higher at active strengths for occasional-use males relative to sex- and/or frequency-matched counterparts (ps < 0.05; via exploratory follow-up for "High" and Sedation/impairment). THC and metabolites tended to be highest in frequent-use males. These findings contrast with previous evidence of greater cannabis sensitivity among females and point toward future investigation into sex-dependent exposure thresholds for tolerance development/escalation. Sex and frequency of use are both implicated in cannabis use disorder risk, and consideration of their interaction is critical in characterizing the acute effects of, and tolerance to, cannabis.
Authors
- Ziva D. Cooper (ORCID: https://orcid.org/0000-0001-8001-2332)
- Alisha Eversole (ORCID: https://orcid.org/0000-0002-5129-0752)
- Katherine E. Hampilos (ORCID: https://orcid.org/0000-0003-0739-8077)
- Daniele Piomelli (ORCID: https://orcid.org/0000-0002-2983-774X)
- Stephanie Lake (ORCID: https://orcid.org/0000-0002-4095-8016)
- Holly R. Middlekauff (ORCID: https://orcid.org/0000-0001-7848-8585)
- TIMOTHY W. FONG
- Conor H. Murray (ORCID: https://orcid.org/0000-0001-9954-7601)
- Suzette M. Evans (ORCID: https://orcid.org/0000-0002-5397-2853)
- Samantha L. Baglot (ORCID: https://orcid.org/0000-0001-8898-2122)
- Alexa Torrens (ORCID: https://orcid.org/0000-0001-7075-5669)
- Elisa Pabon (ORCID: https://orcid.org/0000-0001-6669-7259)
- Margaret Haney (ORCID: https://orcid.org/0000-0002-1220-9528)
- Adren Tran (ORCID: https://orcid.org/0009-0004-0671-7202)
Institutions
- University of California, Los Angeles (US)
- University of California, Irvine (US)
- Columbia University Irving Medical Center (US)
- New York State Psychiatric Institute (US)
- Charles R. Drew University of Medicine and Science (US)
Publication Details
- Journal
- Neuropsychopharmacology
- Published
- 2026-10-29
- DOI
- https://doi.org/10.1038/s41386-026-02571-3
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Canadian Institutes of Health Research
- National Institute on Drug Abuse
- National Institute of General Medical Sciences
- National Center for Advancing Translational Sciences
- Clinical and Translational Science Institute, University of California, Los Angeles